Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
Public ClinicalTrials.gov record NCT00075829. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study is designed as a Phase III, multi-center trial of tandem autologous transplants versus the strategy of autologous followed by Human Leukocyte Antigen (HLA)-matched sibling non-myeloablative allogeneic transplant. Study subjects will be biologically assigned to the appropriate arm depending on the availability of an HLA-matched sibling. There is a nested randomized phase III trial of observation versus maintenance therapy following the second autologous transplant for patients on the tandem autologous transplant arm.
Study identification
- NCT ID
- NCT00075829
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 710 participants
Conditions and interventions
Conditions
Interventions
- One Autologous Transplant Procedure
- Non-Myeloablative Allogeneic Transplant Procedure
- Second Autologous Transplant Procedure
- Thalidomide Drug
- Dexamethasone Drug
- Observation Behavioral
Procedure · Drug · Behavioral
Eligibility (public fields only)
- Age range
- Up to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2003 (Type not available)
- Primary completion
- Jun 2012 (Actual)
- Completion
- Mar 2013 (Actual)
- Last update posted
- Nov 1, 2021
2003 – 2013
United States locations
- U.S. sites
- 36
- U.S. states
- 26
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| City of Hope Samaritan | Phoenix | Arizona | 85006 | — |
| City of Hope National Medical Center | Duarte | California | 91010-3000 | — |
| Scripps Clinic/Green Hospital | La Jolla | California | 92037-1027 | — |
| UCSD Medical Center | La Jolla | California | 92093 | — |
| Stanford Hospital and Clinics | Stanford | California | 94305 | — |
| Colorado Blood Cancer Institute | Denver | Colorado | 80218 | — |
| University of Florida College of Medicine (Shands) | Gainesville | Florida | 32610-100277 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| BMT Group of Georgia/Northside Hospital | Atlanta | Georgia | 30342 | — |
| Loyola University | Maywood | Illinois | 60156 | — |
| IBMT (Indiana Blood and Marrow Transplant) at St Francis Franciscan Health | Indianapolis | Indiana | 46237 | — |
| Wichita CCOP | Wichita | Kansas | 67214 | — |
| Tufts - New England Medical Center | Boston | Massachusetts | 02111 | — |
| DFCI/Brigham & Women's | Boston | Massachusetts | 02114 | — |
| University of Michigan Medical Center | Ann Arbor | Michigan | 48109-0942 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10021 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Jewish Hospital BMT Program | Cincinnati | Ohio | 45236 | — |
| University Hospitals of Cleveland/Case Western | Cleveland | Ohio | 44106 | — |
| University of Oklahoma Medical Center | Oklahoma City | Oklahoma | 73104 | — |
| Oregon Health Sciences University (A) | Portland | Oregon | 97239-3098 | — |
| University of Pennsylvania Cancer Center | Philadelphia | Pennsylvania | 19104 | — |
| Fox Chase - Temple University - BMT Program | Philadelphia | Pennsylvania | 19111-2442 | — |
| Vanderbilt University | Nashville | Tennessee | 37232 | — |
| Baylor College of Medicine/The Methodist Hospital | Houston | Texas | 77030 | — |
| University of Texas/MD Anderson Cancer Research Center | Houston | Texas | 77030 | — |
| Texas Transplant Institute | San Antonio | Texas | 78229 | — |
| Utah BMT/Univ of Utah Med School | Salt Lake City | Utah | 84132 | — |
| Virginia Commonwealth University MCV Hospitals | Richmond | Virginia | 23298 | — |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | 98109-1024 | — |
| University of Wisconsin Hospitals & Clinics | Madison | Wisconsin | 53792-6164 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00075829, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 1, 2021 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00075829 live on ClinicalTrials.gov.